O	O	0	11	Involvement	Involvement	B-NP	NN	O	0	ROOT	O
O	O	12	14	of	of	B-PP	IN	O	1	NMOD	O
O	O	15	18	the	the	B-NP	DT	O	7	NMOD	O
T15	B-Entity	19	20	N	N	I-NP	NN	B-protein	7	NMOD	B-protein
T15	I-Entity	20	21	-	-	B-NP	HYPH	I-protein	7	NMOD	I-protein
T15	I-Entity	21	29	terminal	terminal	I-NP	JJ	I-protein	7	NMOD	I-protein
T15	I-Entity	30	36	region	region	I-NP	NN	I-protein	2	PMOD	I-protein
O	O	37	39	of	of	B-PP	IN	O	7	NMOD	O
O	O	40	43	the	the	B-NP	DT	O	16	NMOD	O
O	O	44	49	human	human	I-NP	JJ	B-protein	16	NMOD	B-protein
T1	B-Protein	50	67	mineralocorticoid	mineralocorticoid	I-NP	NN	I-protein	16	NMOD	I-protein
T1	I-Protein	68	76	receptor	receptor	I-NP	NN	I-protein	16	NMOD	I-protein
T16	B-Entity	77	84	hormone	hormone	I-NP	NN	I-protein	16	NMOD	I-protein
T16	I-Entity	84	85	-	-	O	HYPH	I-protein	16	NMOD	I-protein
T16	I-Entity	85	92	binding	bind	B-NP	VBG	I-protein	16	NMOD	I-protein
T16	I-Entity	93	99	domain	domain	I-NP	NN	I-protein	8	PMOD	I-protein
O	O	100	102	in	in	B-PP	IN	O	1	NMOD	O
O	O	103	110	agonist	agonist	B-NP	NN	O	21	NMOD	O
O	O	111	114	and	and	I-NP	CC	O	21	NMOD	O
O	O	115	125	antagonist	antagonist	I-NP	NN	O	21	NMOD	O
O	O	126	133	binding	binding	I-NP	NN	O	17	PMOD	O
O	O	134	136	as	as	B-SBAR	IN	O	1	NMOD	O
O	O	137	145	revealed	reveal	B-VP	VBN	O	22	SBAR	O
O	O	146	148	by	by	B-PP	IN	O	23	VMOD	O
O	O	149	150	a	a	B-NP	DT	O	28	NMOD	O
O	O	151	154	new	new	I-NP	JJ	B-protein	28	NMOD	B-protein
O	O	155	165	monoclonal	monoclonal	I-NP	JJ	I-protein	28	NMOD	I-protein
O	O	166	174	antibody	antibody	I-NP	NN	I-protein	24	PMOD	I-protein
O	O	174	175	.	.	O	.	O	1	P	O

O	O	177	179	To	To	B-VP	TO	O	2	VMOD	O
O	O	180	184	gain	gain	I-VP	VB	O	21	VMOD	O
O	O	185	186	a	a	B-NP	DT	O	5	NMOD	O
O	O	187	193	better	good	I-NP	JJR	O	5	NMOD	O
O	O	194	207	understanding	understanding	I-NP	NN	O	2	OBJ	O
O	O	208	210	of	of	B-PP	IN	O	5	NMOD	O
O	O	211	214	the	the	B-NP	DT	O	8	NMOD	O
O	O	215	224	mechanism	mechanism	I-NP	NN	O	6	PMOD	O
O	O	225	227	of	of	B-PP	IN	O	8	NMOD	O
O	O	228	235	binding	bind	B-VP	VBG	O	9	PMOD	O
O	O	236	238	to	to	B-PP	TO	O	10	VMOD	O
O	O	239	242	the	the	B-NP	DT	O	15	NMOD	O
O	O	243	248	human	human	I-NP	JJ	B-protein	15	NMOD	B-protein
T2	B-Protein	249	266	mineralocorticoid	mineralocorticoid	I-NP	NN	I-protein	15	NMOD	I-protein
T2	I-Protein	267	275	receptor	receptor	I-NP	NN	I-protein	11	PMOD	I-protein
O	O	276	277	(	(	O	(	O	18	DEP	O
T3	B-Protein	277	280	hMR	hMR	B-NP	NN	B-protein	18	DEP	B-protein
O	O	280	281	)	)	O	)	O	15	NMOD	O
O	O	281	282	,	,	O	,	O	21	P	O
O	O	283	285	we	we	B-NP	PRP	O	21	SUB	O
O	O	286	295	developed	develop	B-VP	VBD	O	0	ROOT	O
O	O	296	297	a	a	B-NP	DT	O	23	NMOD	O
O	O	298	301	new	new	I-NP	JJ	O	21	OBJ	O
O	O	302	312	monoclonal	monoclonal	I-NP	JJ	B-protein	25	NMOD	B-protein
O	O	313	321	antibody	antibody	I-NP	NN	I-protein	23	NMOD	I-protein
O	O	322	323	(	(	O	(	O	28	DEP	O
O	O	323	326	mAb	mAb	B-NP	NN	B-protein	28	DEP	B-protein
O	O	326	327	)	)	O	)	O	25	NMOD	O
O	O	328	334	raised	raise	B-VP	VBN	O	23	NMOD	O
O	O	335	342	against	against	B-PP	IN	O	29	VMOD	O
O	O	343	346	the	the	B-NP	DT	O	35	NMOD	O
T17	B-Entity	347	354	hormone	hormone	I-NP	NN	B-protein	35	NMOD	B-protein
T17	I-Entity	354	355	-	-	O	HYPH	I-protein	35	NMOD	I-protein
T17	I-Entity	355	362	binding	bind	B-VP	VBG	I-protein	35	NMOD	I-protein
T17	I-Entity	363	369	domain	domain	B-NP	NN	I-protein	30	PMOD	I-protein
O	O	370	371	(	(	O	(	O	38	DEP	O
T18	B-Entity	371	374	HBD	HBD	B-NP	NN	B-protein	38	DEP	B-protein
O	O	374	375	)	)	O	)	O	35	NMOD	O
O	O	375	376	.	.	O	.	O	21	P	O

O	O	377	380	For	For	B-PP	IN	O	6	VMOD	O
O	O	381	385	this	this	B-NP	DT	O	3	NMOD	O
O	O	386	393	purpose	purpose	I-NP	NN	O	1	PMOD	O
O	O	393	394	,	,	O	,	O	6	P	O
O	O	395	399	mice	mouse	B-NP	NNS	O	6	SUB	O
O	O	400	404	were	be	B-VP	VBD	O	0	ROOT	O
O	O	405	414	immunized	immunize	I-VP	VBN	O	6	VC	O
O	O	415	419	with	with	B-PP	IN	O	7	VMOD	O
O	O	420	421	a	a	B-NP	DT	O	11	NMOD	O
O	O	422	428	fusion	fusion	I-NP	NN	B-protein	11	NMOD	B-protein
O	O	429	436	protein	protein	I-NP	NN	I-protein	8	PMOD	I-protein
O	O	437	446	including	include	B-PP	VBG	O	11	NMOD	O
O	O	447	450	the	the	B-NP	DT	O	17	NMOD	O
O	O	451	459	sequence	sequence	I-NP	NN	O	17	NMOD	O
T19	B-Entity	460	466	Thr729	Thr729	I-NP	NN	B-protein	17	NMOD	B-protein
T19	I-Entity	466	467	-	-	B-NP	HYPH	I-protein	17	NMOD	I-protein
T19	I-Entity	467	473	Lys984	Lys984	I-NP	NN	I-protein	12	PMOD	I-protein
O	O	474	476	of	of	B-PP	IN	O	17	NMOD	O
T4	B-Protein	477	480	hMR	hMR	B-NP	NN	B-protein	18	PMOD	B-protein
O	O	480	481	.	.	O	.	O	6	P	O

O	O	482	487	After	After	B-PP	IN	O	7	VMOD	O
O	O	488	493	ELISA	ELISA	B-NP	NN	O	3	NMOD	O
O	O	494	503	screening	screening	I-NP	NN	O	1	PMOD	O
O	O	503	504	,	,	O	,	O	7	P	O
O	O	505	508	mAb	mAb	B-NP	NN	B-protein	6	NMOD	B-protein
O	O	509	513	18C7	18C7	I-NP	NN	I-protein	7	SUB	I-protein
O	O	514	517	was	be	B-VP	VBD	O	0	ROOT	O
O	O	518	526	selected	select	I-VP	VBN	O	7	VC	O
O	O	527	530	for	for	B-PP	IN	O	8	VMOD	O
O	O	531	534	its	its	B-NP	PRP$	O	11	NMOD	O
O	O	535	546	specificity	specificity	I-NP	NN	O	9	PMOD	O
O	O	547	554	towards	towards	B-PP	IN	O	11	NMOD	O
O	O	555	558	the	the	B-NP	DT	O	14	NMOD	O
T20	B-Entity	559	562	HBD	HBD	I-NP	NN	B-protein	12	PMOD	B-protein
O	O	562	563	.	.	O	.	O	7	P	O

O	O	564	568	This	This	B-NP	DT	O	2	NMOD	O
O	O	569	577	antibody	antibody	I-NP	NN	O	3	SUB	O
O	O	578	588	recognized	recognize	B-VP	VBD	O	0	ROOT	O
O	O	589	593	both	both	O	CC	O	10	NMOD	O
O	O	594	597	the	the	B-NP	DT	O	10	NMOD	O
O	O	598	607	denatured	denature	I-NP	VBN	O	10	NMOD	O
O	O	608	611	and	and	I-NP	CC	O	10	NMOD	O
O	O	612	618	native	native	I-NP	JJ	B-protein	10	NMOD	B-protein
T5	B-Protein	619	621	MR	MR	I-NP	NN	I-protein	10	NMOD	I-protein
O	O	622	627	forms	form	I-NP	NNS	I-protein	25	NMOD	I-protein
O	O	627	628	,	,	O	,	O	25	P	O
O	O	629	631	as	as	B-CONJP	RB	O	25	NMOD	O
O	O	632	636	well	well	I-CONJP	RB	O	12	DEP	O
O	O	637	639	as	as	I-CONJP	IN	O	12	DEP	O
O	O	640	643	the	the	B-NP	DT	O	20	NMOD	O
O	O	644	650	hetero	hetero	I-NP	AFX	B-protein	20	NMOD	B-protein
O	O	650	651	-	-	I-NP	HYPH	I-protein	20	NMOD	I-protein
O	O	651	661	oligomeric	oligomeric	I-NP	JJ	I-protein	20	NMOD	I-protein
T6	B-Protein	662	664	MR	MR	I-NP	NN	I-protein	20	NMOD	I-protein
T21	B-Entity	665	669	form	form	I-NP	NN	I-protein	25	NMOD	I-protein
O	O	670	673	and	and	O	CC	O	25	NMOD	O
O	O	674	677	the	the	B-NP	DT	O	25	NMOD	O
O	O	678	689	transformed	transform	I-NP	VBN	B-protein	25	NMOD	B-protein
T7	B-Protein	690	692	MR	MR	I-NP	NN	I-protein	25	NMOD	I-protein
O	O	693	698	state	state	I-NP	NN	I-protein	3	OBJ	I-protein
O	O	698	699	.	.	O	.	O	3	P	O

O	O	700	702	By	By	B-PP	IN	O	11	VMOD	O
O	O	703	708	using	use	B-VP	VBG	O	1	PMOD	O
O	O	709	716	several	several	B-NP	JJ	O	2	OBJ	O
T22	B-Entity	717	720	HBD	HBD	I-NP	NN	B-protein	5	NMOD	B-protein
T22	I-Entity	721	733	subfragments	subfragment	I-NP	NNS	I-protein	3	NMOD	I-protein
O	O	733	734	,	,	O	,	O	11	P	O
O	O	735	738	the	the	B-NP	DT	O	10	NMOD	O
T23	B-Entity	739	742	mAb	mAb	I-NP	NN	B-protein	10	NMOD	B-protein
T23	I-Entity	743	747	18C7	18C7	I-NP	NN	I-protein	10	NMOD	I-protein
T23	I-Entity	748	755	epitope	epitope	I-NP	NN	I-protein	11	SUB	I-protein
O	O	756	759	was	be	B-VP	VBD	O	0	ROOT	O
O	O	760	767	located	locate	I-VP	VBN	O	11	PRD	O
O	O	768	770	in	in	B-PP	IN	O	12	AMOD	O
O	O	771	774	the	the	B-NP	DT	O	18	NMOD	O
T24	B-Entity	775	776	N	N	I-NP	NN	B-protein	18	NMOD	B-protein
T24	I-Entity	776	777	-	-	B-NP	HYPH	I-protein	18	NMOD	I-protein
T24	I-Entity	777	785	terminal	terminal	I-NP	JJ	I-protein	18	NMOD	I-protein
T24	I-Entity	786	792	region	region	I-NP	NN	I-protein	13	PMOD	I-protein
O	O	793	795	of	of	B-PP	IN	O	18	NMOD	O
O	O	796	799	the	the	B-NP	DT	O	21	NMOD	O
T25	B-Entity	800	803	HBD	HBD	I-NP	NN	B-protein	19	PMOD	B-protein
O	O	804	808	from	from	B-PP	IN	O	12	AMOD	O
T26	B-Entity	809	815	Thr729	Thr729	B-NP	NN	B-protein	22	PMOD	B-protein
T26	I-Entity	816	818	to	to	B-PP	TO	O	22	PMOD	O
T26	I-Entity	819	825	Leu765	Leu765	B-NP	NN	B-protein	22	PMOD	B-protein
O	O	825	826	.	.	O	.	O	11	P	O

O	O	827	829	We	We	B-NP	PRP	O	3	SUB	O
O	O	830	834	then	then	B-ADVP	RB	O	3	VMOD	O
O	O	835	842	studied	study	B-VP	VBD	O	0	ROOT	O
O	O	843	846	the	the	B-NP	DT	O	5	NMOD	O
O	O	847	853	effect	effect	I-NP	NN	O	3	OBJ	O
O	O	854	856	of	of	B-PP	IN	O	5	NMOD	O
O	O	857	860	the	the	B-NP	DT	O	8	NMOD	O
O	O	861	869	antibody	antibody	I-NP	NN	O	6	PMOD	O
O	O	870	872	on	on	B-PP	IN	O	5	NMOD	O
O	O	873	884	aldosterone	aldosterone	B-NP	NN	O	12	NMOD	O
O	O	885	888	and	and	O	CC	O	12	NMOD	O
O	O	889	901	progesterone	progesterone	B-NP	NN	O	13	NMOD	O
O	O	902	909	binding	binding	B-NP	NN	O	9	PMOD	O
O	O	910	912	to	to	B-PP	TO	O	13	NMOD	O
O	O	913	916	the	the	B-NP	DT	O	16	NMOD	O
T8	B-Protein	917	920	hMR	hMR	I-NP	NN	B-protein	14	PMOD	B-protein
O	O	920	921	.	.	O	.	O	3	P	O

O	O	922	926	When	When	B-ADVP	WRB	O	10	VMOD	O
O	O	927	931	18C7	18C7	B-NP	NN	B-protein	3	SUB	B-protein
O	O	932	935	was	be	B-VP	VBD	O	1	SBAR	O
O	O	936	945	incubated	incubate	I-VP	VBN	O	3	VC	O
O	O	946	950	with	with	B-PP	IN	O	4	VMOD	O
O	O	951	959	liganded	liganded	B-NP	JJ	B-protein	7	NMOD	B-protein
T9	B-Protein	960	962	MR	MR	I-NP	NN	I-protein	5	PMOD	I-protein
O	O	962	963	,	,	O	,	O	10	P	O
O	O	964	966	it	it	B-NP	PRP	O	10	SUB	O
O	O	967	970	was	be	B-VP	VBD	O	0	ROOT	O
O	O	971	975	able	able	B-ADJP	JJ	O	10	PRD	O
O	O	976	978	to	to	B-VP	TO	O	14	VMOD	O
O	O	979	985	partly	partly	I-VP	RB	O	14	VMOD	O
O	O	986	994	displace	displace	I-VP	VB	O	11	AMOD	O
O	O	995	996	(	(	O	(	O	18	DEP	O
O	O	996	998	20	20	B-NP	CD	O	17	NMOD	O
O	O	998	999	%	%	I-NP	NN	O	18	DEP	O
O	O	999	1000	)	)	O	)	O	14	VMOD	O
O	O	1001	1004	the	the	B-NP	DT	O	20	NMOD	O
O	O	1005	1012	hormone	hormone	I-NP	NN	O	14	OBJ	O
O	O	1013	1017	from	from	B-PP	IN	O	14	VMOD	O
O	O	1018	1021	its	its	B-NP	PRP$	O	24	NMOD	O
O	O	1022	1029	binding	bind	I-NP	VBG	O	24	NMOD	O
O	O	1030	1034	site	site	I-NP	NN	O	21	PMOD	O
O	O	1034	1035	.	.	O	.	O	10	P	O

O	O	1036	1040	When	When	B-ADVP	WRB	O	14	VMOD	O
O	O	1041	1045	18C7	18C7	B-NP	NN	B-protein	3	SUB	B-protein
O	O	1046	1049	was	be	B-VP	VBD	O	1	SBAR	O
O	O	1050	1059	incubated	incubate	I-VP	VBN	O	3	VC	O
O	O	1060	1064	with	with	B-PP	IN	O	4	VMOD	O
T10	B-Protein	1065	1067	MR	MR	B-NP	NN	B-protein	5	PMOD	B-protein
O	O	1068	1074	before	before	B-PP	IN	O	4	VMOD	O
O	O	1075	1086	aldosterone	aldosterone	B-NP	NN	O	10	NMOD	O
O	O	1087	1089	or	or	I-NP	CC	O	10	NMOD	O
O	O	1090	1102	progesterone	progesterone	I-NP	NN	O	7	PMOD	O
O	O	1102	1103	,	,	O	,	O	14	P	O
O	O	1104	1107	the	the	B-NP	DT	O	13	NMOD	O
O	O	1108	1116	antibody	antibody	I-NP	NN	O	14	SUB	O
O	O	1117	1126	inhibited	inhibit	B-VP	VBD	O	0	ROOT	O
O	O	1127	1129	75	75	B-NP	CD	O	18	NMOD	O
O	O	1129	1130	-	-	I-NP	HYPH	O	18	NMOD	O
O	O	1130	1132	80	80	I-NP	CD	O	18	NMOD	O
O	O	1132	1133	%	%	I-NP	NN	O	14	OBJ	O
O	O	1134	1136	of	of	B-PP	IN	O	18	NMOD	O
O	O	1137	1140	the	the	B-NP	DT	O	21	NMOD	O
O	O	1141	1148	binding	binding	I-NP	NN	O	19	PMOD	O
O	O	1148	1149	.	.	O	.	O	14	P	O

O	O	1150	1153	The	The	B-NP	DT	O	2	NMOD	O
O	O	1154	1160	effect	effect	I-NP	NN	O	8	SUB	O
O	O	1161	1163	of	of	B-PP	IN	O	2	NMOD	O
O	O	1164	1168	18C7	18C7	B-NP	NN	B-protein	3	PMOD	B-protein
O	O	1169	1171	on	on	B-PP	IN	O	2	NMOD	O
O	O	1172	1175	the	the	B-NP	DT	O	7	NMOD	O
O	O	1176	1183	binding	binding	I-NP	NN	O	5	PMOD	O
O	O	1184	1187	was	be	B-VP	VBD	O	0	ROOT	O
O	O	1188	1195	similar	similar	B-ADJP	JJ	O	8	PRD	O
O	O	1196	1200	with	with	B-PP	IN	O	9	AMOD	O
O	O	1201	1205	both	both	B-NP	DT	O	12	NMOD	O
O	O	1206	1214	hormones	hormone	I-NP	NNS	O	10	PMOD	O
O	O	1214	1215	.	.	O	.	O	8	P	O

O	O	1216	1217	A	A	B-NP	DT	O	4	NMOD	O
O	O	1218	1225	sucrose	sucrose	I-NP	NN	O	4	NMOD	O
O	O	1226	1234	gradient	gradient	I-NP	NN	O	4	NMOD	O
O	O	1235	1243	analysis	analysis	I-NP	NN	O	5	SUB	O
O	O	1244	1253	indicated	indicate	B-VP	VBD	O	0	ROOT	O
O	O	1254	1257	the	the	B-NP	DT	O	8	NMOD	O
O	O	1258	1270	simultaneous	simultaneous	I-NP	JJ	O	8	NMOD	O
O	O	1271	1279	presence	presence	I-NP	NN	O	5	OBJ	O
O	O	1280	1282	of	of	B-PP	IN	O	8	NMOD	O
O	O	1283	1286	two	two	B-NP	CD	O	11	NMOD	O
O	O	1287	1292	kinds	kind	I-NP	NNS	O	9	PMOD	O
O	O	1293	1295	of	of	B-PP	IN	O	11	NMOD	O
O	O	1296	1304	receptor	receptor	B-NP	NN	B-protein	14	NMOD	B-protein
O	O	1305	1314	complexes	complex	I-NP	NNS	I-protein	12	PMOD	I-protein
O	O	1314	1315	:	:	O	:	O	5	P	O
O	O	1316	1319	the	the	B-NP	DT	O	20	NMOD	O
O	O	1320	1327	steroid	steroid	I-NP	NN	B-protein	20	NMOD	B-protein
O	O	1327	1328	-	-	B-NP	HYPH	I-protein	20	NMOD	I-protein
T11	B-Protein	1328	1330	MR	MR	I-NP	NN	I-protein	20	NMOD	I-protein
T27	B-Entity	1331	1338	complex	complex	I-NP	NN	I-protein	26	NMOD	I-protein
O	O	1339	1342	and	and	O	CC	O	26	NMOD	O
O	O	1343	1346	the	the	B-NP	DT	O	26	NMOD	O
T28	B-Entity	1347	1355	antibody	antibody	I-NP	NN	B-protein	26	NMOD	B-protein
T28	I-Entity	1355	1356	-	-	B-NP	HYPH	I-protein	26	NMOD	I-protein
T12,T28	B-Protein,I-Entity	1356	1358	MR	MR	I-NP	NN	I-protein	26	NMOD	I-protein
T28	I-Entity	1359	1366	complex	complex	I-NP	NN	I-protein	5	VMOD	I-protein
O	O	1366	1367	.	.	O	.	O	5	P	O

O	O	1368	1373	After	After	B-PP	IN	O	14	VMOD	O
O	O	1374	1377	its	its	B-NP	PRP$	O	4	NMOD	O
O	O	1378	1388	associated	associate	I-NP	VBN	O	4	NMOD	O
O	O	1389	1397	proteins	protein	I-NP	NNS	O	1	PMOD	O
O	O	1397	1398	,	,	O	,	O	14	P	O
O	O	1399	1409	especially	especially	B-ADVP	RB	O	12	NMOD	O
O	O	1410	1413	the	the	B-NP	DT	O	12	NMOD	O
O	O	1414	1418	heat	heat	I-NP	NN	B-protein	12	NMOD	B-protein
O	O	1418	1419	-	-	B-NP	HYPH	I-protein	12	NMOD	I-protein
O	O	1419	1424	shock	shock	I-NP	NN	I-protein	12	NMOD	I-protein
O	O	1425	1432	protein	protein	I-NP	NN	I-protein	12	NMOD	I-protein
T13	B-Protein	1433	1438	hsp90	hsp90	I-NP	NN	B-protein	14	SUB	B-protein
O	O	1438	1439	,	,	O	,	O	12	P	O
O	O	1440	1443	had	have	B-VP	VBD	O	26	VMOD	O
O	O	1444	1448	been	be	I-VP	VBN	O	14	VC	O
O	O	1449	1454	cross	cross	B-ADJP	AFX	O	15	PRD	O
O	O	1454	1455	-	-	O	HYPH	O	16	AMOD	O
O	O	1455	1461	linked	link	B-VP	VBN	O	17	SBAR	O
O	O	1462	1466	with	with	B-PP	IN	O	18	VMOD	O
O	O	1467	1470	the	the	B-NP	DT	O	21	NMOD	O
T14	B-Protein	1471	1474	hMR	hMR	I-NP	NN	B-protein	19	PMOD	B-protein
O	O	1475	1477	by	by	B-PP	IN	O	18	VMOD	O
O	O	1478	1498	dimethylpimelimidate	dimethylpimelimidate	B-NP	NN	O	22	PMOD	O
O	O	1498	1499	,	,	O	,	O	14	P	O
O	O	1500	1504	18C7	18C7	B-NP	NN	B-protein	26	SUB	B-protein
O	O	1505	1508	was	be	B-VP	VBD	O	0	ROOT	O
O	O	1509	1514	still	still	B-ADVP	RB	O	26	VMOD	O
O	O	1515	1519	able	able	B-ADJP	JJ	O	26	PRD	O
O	O	1520	1522	to	to	B-VP	TO	O	30	VMOD	O
O	O	1523	1528	react	react	I-VP	VB	O	28	AMOD	O
O	O	1529	1533	with	with	B-PP	IN	O	30	VMOD	O
O	O	1534	1537	the	the	B-NP	DT	O	33	NMOD	O
O	O	1538	1546	receptor	receptor	I-NP	NN	O	31	PMOD	O
O	O	1546	1547	.	.	O	.	O	26	P	O

O	O	1548	1551	Our	Our	B-NP	PRP$	O	2	NMOD	O
O	O	1552	1559	results	result	I-NP	NNS	O	3	SUB	O
O	O	1560	1569	indicated	indicate	B-VP	VBD	O	0	ROOT	O
O	O	1570	1574	that	that	B-SBAR	IN	O	3	VMOD	O
O	O	1575	1578	the	the	B-NP	DT	O	6	NMOD	O
T29	B-Entity	1579	1586	epitope	epitope	I-NP	NN	B-protein	10	SUB	B-protein
O	O	1587	1597	recognized	recognize	B-VP	VBN	O	6	NMOD	O
O	O	1598	1600	by	by	B-PP	IN	O	7	VMOD	O
O	O	1601	1605	18C7	18C7	B-NP	NN	B-protein	8	PMOD	B-protein
O	O	1606	1609	was	be	B-VP	VBD	O	4	SBAR	O
O	O	1610	1618	directly	directly	I-VP	RB	O	10	VMOD	O
O	O	1619	1629	implicated	implicate	I-VP	VBN	O	10	VC	O
O	O	1630	1632	in	in	B-PP	IN	O	12	VMOD	O
O	O	1633	1640	hormone	hormone	B-NP	NN	O	15	NMOD	O
O	O	1641	1648	binding	binding	I-NP	NN	O	13	PMOD	O
O	O	1648	1649	.	.	O	.	O	3	P	O

O	O	1650	1653	The	The	B-NP	DT	O	2	NMOD	O
O	O	1654	1658	lack	lack	I-NP	NN	O	42	SUB	O
O	O	1659	1661	of	of	B-PP	IN	O	2	NMOD	O
O	O	1662	1669	steroid	steroid	B-NP	NN	O	5	NMOD	O
O	O	1670	1677	binding	binding	I-NP	NN	O	3	PMOD	O
O	O	1678	1680	of	of	B-PP	IN	O	5	NMOD	O
T30	B-Entity	1681	1684	HBD	HBD	B-NP	NN	B-protein	8	NMOD	B-protein
O	O	1685	1692	mutants	mutant	I-NP	NNS	I-protein	6	PMOD	I-protein
O	O	1693	1697	with	with	B-PP	IN	O	5	NMOD	O
O	O	1698	1701	the	the	B-NP	DT	O	14	NMOD	O
T31	B-Entity	1702	1708	Thr729	Thr729	I-NP	NN	B-DNA	14	NMOD	B-DNA
T31	I-Entity	1708	1709	-	-	B-NP	HYPH	I-DNA	14	NMOD	I-DNA
T31	I-Entity	1709	1715	Leu765	Leu765	I-NP	NN	I-DNA	14	NMOD	I-DNA
T31	I-Entity	1716	1724	sequence	sequence	I-NP	NN	I-DNA	9	PMOD	I-DNA
O	O	1725	1732	deleted	delete	B-VP	VBN	O	14	NMOD	O
O	O	1733	1734	[	[	O	(	O	41	DEP	O
O	O	1734	1743	Jalaguier	Jalaguier	B-NP	NNP	O	23	NMOD	O
O	O	1743	1744	,	,	O	,	O	23	P	O
O	O	1745	1752	Mesnier	Mesnier	B-NP	NNP	O	23	NMOD	O
O	O	1752	1753	,	,	O	,	O	23	P	O
O	O	1754	1759	Leger	Leger	B-NP	NNP	O	23	NMOD	O
O	O	1760	1763	and	and	O	CC	O	23	NMOD	O
O	O	1764	1769	Auzou	Auzou	B-NP	NNP	O	34	NMOD	O
O	O	1770	1771	(	(	O	(	O	26	DEP	O
O	O	1771	1775	1996	1996	B-NP	CD	O	26	DEP	O
O	O	1775	1776	)	)	O	)	O	34	NMOD	O
O	O	1777	1778	J	J	B-NP	NNP	O	30	NMOD	O
O	O	1778	1779	.	.	I-NP	.	O	30	P	O
O	O	1779	1786	Steroid	Steroid	I-NP	NNP	O	30	NMOD	O
O	O	1787	1794	Biochem	Biochem	I-NP	NNP	O	32	NMOD	O
O	O	1794	1795	.	.	I-NP	.	O	32	P	O
O	O	1795	1798	Mol	Mol	I-NP	NNP	O	34	NMOD	O
O	O	1798	1799	.	.	I-NP	.	O	34	NMOD	O
O	O	1799	1803	Biol	Biol	I-NP	NNP	O	41	DEP	O
O	O	1803	1804	.	.	B-PP	IN	O	34	NMOD	O
O	O	1804	1806	57	57	B-NP	CD	O	40	NMOD	O
O	O	1806	1807	,	,	I-NP	,	O	40	P	O
O	O	1808	1810	43	43	I-NP	CD	O	40	NMOD	O
O	O	1810	1811	-	-	B-NP	HYPH	O	40	P	O
O	O	1811	1813	50	50	I-NP	CD	O	35	PMOD	O
O	O	1813	1814	]	]	O	)	O	2	NMOD	O
O	O	1815	1823	supports	support	B-VP	VBZ	O	0	ROOT	O
O	O	1824	1828	this	this	B-NP	DT	O	44	NMOD	O
O	O	1829	1839	hypothesis	hypothesis	I-NP	NN	O	42	OBJ	O
O	O	1839	1840	.	.	O	.	O	42	P	O

O	O	1841	1848	Because	Because	B-PP	IN	O	12	VMOD	O
O	O	1849	1851	of	of	I-PP	IN	O	1	PMOD	O
O	O	1852	1855	the	the	B-NP	DT	O	5	NMOD	O
O	O	1856	1863	similar	similar	I-NP	JJ	O	5	NMOD	O
O	O	1864	1874	behaviours	behaviour	I-NP	NNS	O	1	PMOD	O
O	O	1875	1877	of	of	B-PP	IN	O	5	NMOD	O
O	O	1878	1889	aldosterone	aldosterone	B-NP	NN	O	9	NMOD	O
O	O	1890	1893	and	and	I-NP	CC	O	9	NMOD	O
O	O	1894	1906	progesterone	progesterone	I-NP	NN	O	6	PMOD	O
O	O	1906	1907	,	,	O	,	O	12	P	O
O	O	1908	1910	we	we	B-NP	PRP	O	12	SUB	O
O	O	1911	1919	conclude	conclude	B-VP	VBP	O	0	ROOT	O
O	O	1920	1924	that	that	B-SBAR	IN	O	12	VMOD	O
O	O	1925	1928	the	the	B-NP	DT	O	21	NMOD	O
T32	B-Entity	1929	1930	N	N	I-NP	NN	B-protein	21	NMOD	B-protein
T32	I-Entity	1930	1931	-	-	O	HYPH	I-protein	21	NMOD	I-protein
T32	I-Entity	1931	1939	terminal	terminal	B-NP	JJ	I-protein	21	NMOD	I-protein
T32	I-Entity	1940	1946	Thr729	Thr729	I-NP	NN	I-protein	21	NMOD	I-protein
T32	I-Entity	1946	1947	-	-	B-NP	HYPH	I-protein	21	NMOD	I-protein
T32	I-Entity	1947	1953	Leu765	Leu765	I-NP	NN	I-protein	21	NMOD	I-protein
T32	I-Entity	1954	1960	region	region	I-NP	NN	I-protein	25	SUB	I-protein
O	O	1961	1963	of	of	B-PP	IN	O	21	NMOD	O
O	O	1964	1967	the	the	B-NP	DT	O	24	NMOD	O
T33	B-Entity	1968	1971	HBD	HBD	I-NP	NN	B-protein	22	PMOD	B-protein
O	O	1972	1974	is	be	B-VP	VBZ	O	13	SBAR	O
O	O	1975	1984	similarly	similarly	I-VP	RB	O	25	VMOD	O
O	O	1985	1993	involved	involve	I-VP	VBN	O	25	VC	O
O	O	1994	1996	in	in	B-PP	IN	O	27	VMOD	O
O	O	1997	2000	the	the	B-NP	DT	O	30	NMOD	O
O	O	2001	2008	binding	binding	I-NP	NN	O	28	PMOD	O
O	O	2009	2011	of	of	B-PP	IN	O	30	NMOD	O
O	O	2012	2016	both	both	B-NP	DT	O	33	NMOD	O
O	O	2017	2025	hormones	hormone	I-NP	NNS	O	31	PMOD	O
O	O	2025	2026	.	.	O	.	O	12	P	O
